In this video, Erica Mayer, MD, MPH, from Dana-Farber Cancer Institute in Boston, MA, reviews results from the EMBER-3 trial exploring imlunestrant, with and without abemaciclib, as a novel, all-oral, chemotherapy-free therapy in the treatment of patients with estrogen receptor–positive/HER2-negative breast cancer. Watch Video ›

Updated results from the EMBER-3 trial highlight the potential of imlunestrant, alone or with abemaciclib, as a promising all-oral, chemotherapy-free therapy for advanced estrogen receptor−positive/HER2-negative breast cancer. Watch Video ›

The ELAINE 3 trial explores the potential of lasofoxifene plus abemaciclib to redefine treatment for ESR1-mutated, estrogen receptor (ER)-positive/HER2-negative metastatic breast cancer after CDK4/6 inhibitor progression. Watch Video ›

The phase 3 evERA trial highlights giredestrant plus everolimus as an effective, all-oral therapy for estrogen receptor (ER)-positive/HER2-negative advanced breast cancer following CDK4/6 inhibitor progression. Watch Video ›

The OPERA-02 trial investigated the potential of palazestrant combined with ribociclib to redefine 1L treatment for estrogen receptor (ER)-positive/HER2-negative advanced breast cancer by targeting resistance mechanisms and improving outcomes. Watch Video ›

Discover how groundbreaking therapies targeting ESR1 mutations are transforming the treatment landscape for hormone receptor–positive metastatic breast cancer. Watch Video ›

New insights from the EMBER-3 trial reveal how circulating tumor DNA dynamics can predict treatment efficacy, highlighting the benefits of imlunestrant alone and in combination with abemaciclib for advanced estrogen receptor–positive/HER2-negative breast cancer. Watch Video ›

The ELEVATE study highlights elacestrant-based combinations as a promising all-oral treatment strategy to overcome resistance and improve outcomes in estrogen receptor–positive/HER2-negative metastatic breast cancer. Watch Video ›

The INSEMA trial reveals how axillary surgery and radiotherapy techniques influence dose distribution and regional nodal irradiation in patients with early breast cancer undergoing breast-conserving surgery. Watch Video ›

The INSEMA trial explores the safety and benefits of sentinel lymph node biopsy omission versus completion axillary lymph node dissection in patients with early breast cancer undergoing breast-conserving surgery. Watch Video ›